Connect with us

Cannabis News

Health Canada cannabis guidance exposes “absurd” education gap in healthcare

Published

on

New federal guidance on medical cannabis is drawing attention to a growing gap in Canadian health care: patients are increasingly using cannabis to manage symptoms, but often without consistent clinical education, dosage support or drug interaction screening.

In January 2026, Health Canada published Information on the Medical Uses of Cannabis, a guidance document for consumers that includes contraindications, possible drug interactions, dosing and titration principles, and potential adverse effects.

Legal cannabis products produced and sold in Canada are not licensed to treat specific diseases or symptoms and have not been reviewed to determine whether they are safe or effective for those purposes.

“This is top-to-bottom healthcare,” said Ajay Chahal, PharmD, co-founder of Apothecare. “Health Canada has done the work to put clear guidelines to Canadians, but it’s absurd that patients are still forced to be their own physician educators. We’ve created a reality where patients are forced to turn to budtenders for pseudo-clinical advice, product recommendations for sleep, pain, anxiety or cancer-related symptoms based on anecdotes that work for someone I know. That’s not informed care, it’s a symptom of a system that has failed.”

Health Canada says that the use of cannabis carries health risks that are not yet fully understood and advises Canadians to consult their health care provider before using cannabis for medical purposes.

“That warning should set the system in motion,” said Anushya Vijayaraghevan, PharmD, co-founder of Apothecare. “Patients should not gamble with their health to relieve symptoms. If a patient is taking antidepressants, blood thinners, seizure medications, or has mental health vulnerabilities, the stakes are real. However, patients are often left to make product decisions and trial-and-error dosing with little guidance from the clinical system they are supposed to protect.”

In response to Health Canada’s guidelines, Apothecare is calling for four immediate actions to close the cannabis education gap in Canadian healthcare. First, medical cannabis education should be integrated into the core training of physicians, pharmacists, nurses, and allied health providers, with standardized learning outcomes that address dosage, contraindications, impairment, and drug interactions. Cannabis is already being used by patients across the country, and clinicians need a shared baseline of knowledge to manage it safely and consistently.

Second, clinical cannabis counseling should be established as a standard for patient safety. Canadians deserve access to evidence-based guidance that is medically responsible, consistent across care settings and independent of retail environments. Without clinical advice, patients are often left to navigate complex decisions on their own, increasing the risk of misuse, adverse effects, or missed interactions with other therapies.

Third, continuing education requirements through professional organizations need to be modernized so that clinicians can keep pace as cannabis use becomes more common for symptom management. Continuing education allows health care providers to confidently counsel patients, analyze risk factors, and adapt care as evidence evolves, rather than relying on outdated information or comfort levels.

Finally, cannabis should be treated like other pharmacologically active therapies in routine care. This means standardizing patient disclosure, documenting use in medical records, and supporting appropriate follow-up and monitoring. By moving away from a trial-and-error approach, it will help integrate cannabis into standard care practices and improve patient safety and outcomes.

“This is not about being for or against cannabis,” Vijayaragheva said. “It’s about accountability. The system can’t ignore something this widespread and then act surprised when patients are confused, underinformed or harmed. We have the knowledge and the clinical space to do better, but it needs to be prioritized.”

“This should not be controversial,” Chahal said. “If millions of Canadians use cannabis for medical purposes, then millions of Canadians deserve professional-level education, consistent clinical supervision and clear safety standards.”

For more information:
Apothecare
https://apothecare.ca/

Cannabis News

Maximizing cannabis yields with intercanopy and subcanopy lighting

Published

on

By







Continue Reading

Cannabis News

Transportation Groups Warn Feds Of Marijuana Rescheduling’s ‘Consequences’ For Drug Testing Of Truck Drivers And Pilots

Published

on

By

A coalition of transportation and safety organizations said they have “serious safety concerns” about the Trump administration’s move to federally regulate marijuana.

Led by the American Trucking Association, the groups sent a letter to federal officials Monday asking them to take steps to ensure truck drivers, pilots, transit operators and other safety-sensitive workers continue to be tested for cannabis.

“If employers do not take the necessary steps to preserve the ability of security-sensitive transportation workers to test for marijuana, this change could have significant consequences for the safety of passengers and the entire transportation industry,” wrote Acting Attorney General Todd Blanche, Drug Enforcement Administration (DEA) Administrator Terrance Cole, Health and Human Services Secretary Robert F. Kennedy, and Transportation Secretary J.

The organizations said they understand that federal officials are being “urgently” reorganized under an executive order from President Donald Trump, that they are “deeply concerned that the current process does not adequately take into account agencies responsible for transportation safety or protecting the traveling public” and that they want the agencies to “work together.” ongoing cannabis redistricting hearings and rulemaking process to address these concerns.

In May, the Department of Transportation (DOT) issued new guidelines saying just that Truck drivers, airline pilots and other safety-sensitive workers still cannot use medical marijuana without penalty despite the Trump administration’s move to reschedule.

“Marijuana use is incompatible with safety-sensitive functions,” the department said.

Medical review officers (MROs) who receive drug test results indicating cannabis use cannot rule them out as negative for illegal substance use, even if an employee claims it was a result of state-licensed medical marijuana.

“Currently, there is no way for an MRO to verify that a laboratory-confirmed marijuana drug test result is positive when an employee claims the positive was caused by a state-licensed marijuana product,” the DOT said, explaining that after the reprogramming, medical marijuana dispensed under state law “does not” constitute a drug approved by the Food and Drug Administration (FDA).

The transportation groups said in the new letter that the DOT’s drug-testing program “is in accordance with the Department of Health and Human Services’ (HHS) Mandatory Guidelines for Federal Workplace Drug Testing Programs and HHS-certified laboratories.”

“While DOT has expressed its intention to continue testing marijuana, a commitment we greatly appreciate, it is unclear whether DOT will retain its ability to rely on HHS procedures and certifications after the rescheduling,” they wrote. “Without this alignment, DOT may retain the authority to conduct testing, but lack the scientific and procedural infrastructure to do so.”

“Practically, this would mean that truck and bus drivers, pilots, flight attendants, air traffic controllers, air mechanics, railroad workers, dispatchers and signal workers, transit operators and pipeline workers could continue to perform high-risk safety roles without a reliable means of verifying that they are not actively using marijuana. It relies on controlled substance testing to identify end use and prevent potentially impaired individuals from fulfilling their safety-related obligations. While the planning could create legal or regulatory loopholes, the regulated employer-based drug testing agency warned that the final rules should not jeopardize marijuana testing for safety-sensitive transportation workers.”

“Regardless of the broader policy goals of the review, the federal government should not move forward to preserve transportation drug testing programs and mitigate the risks of increased and unchecked deterioration of our roads, railroads, public transportation systems, pipelines, airspace, and maritime corridors,” the letter says.

The organizations specifically ask federal officials to:

  • Support long-term marijuana testing for all safety-sensitive transportation workers;
  • Confirm the authority of DOT-regulated employers to perform such tests;
  • Ensure HHS laboratory certification and testing guidelines remain available and aligned with DOT’s safety mission; and
  • Establish a coordinated federal strategy to address the transportation security implications of rescheduling.

“The public and the workers who keep our transportation system running safely deserve a process that ensures these safeguards are firmly in place before any final action is taken,” he said. the letter he says

Earlier this month, the House Appropriations Committee approved a provision to allow federal officials to continue requiring government employees and security-sensitive employees, such as truck drivers and airline pilots must be drug tested for marijuana, “regardless of any future change in legal status or schedule.”

This was followed by a press conference organized by prohibitionist groups and a drug-testing industry association, where both Republican lawmakers joined the proclamation. “Cut” to marijuana rescheduling by asserting that safety-sensitive transportation workers can still be punished for testing positive for THC.

Legislators and abolitionist activists argued that moving marijuana to Schedule III would lead to a 1986 executive order signed by President Ronald Reagan defining illegal drugs under the Controlled Substances Act (CSA) in relation to the use of cannabis by truck drivers and other airline employees.

Last October, Transportation Secretary Sean Duffy suggested that President Donald Trump was “putting pressure” on rescheduling cannabis.arguing that marijuana is “truly addictive” and that policy reform on the issue sends a “dangerous” message.

“At a time when the culture is encouraging and celebrating the use of marijuana, we’re not talking about risk,” Duffy said.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Experts say THC percentage is the wrong way to shop for cannabis

Published

on

By


Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media